BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9722070)

  • 1. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.
    Paquette RL; Tran L; Landaw EM
    Bone Marrow Transplant; 1998 Aug; 22(4):351-7. PubMed ID: 9722070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.
    Nishida T; Hamaguchi M; Hirabayashi N; Haneda M; Terakura S; Atsuta Y; Imagama S; Kanie T; Murata M; Taji H; Suzuki R; Morishita Y; Kodera Y
    Bone Marrow Transplant; 2004 Jun; 33(11):1143-50. PubMed ID: 15077133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy.
    Zeigler ZR; Shadduck RK; Nath R; Andrews DF
    Bone Marrow Transplant; 1996 Jan; 17(1):81-6. PubMed ID: 8673060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children.
    Hale GA; Bowman LC; Rochester RJ; Benaim E; Heslop HE; Krance RA; Horwitz EM; Cunningham JM; Tong X; Srivastava DK; Handgretinger R; Jones DP
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):912-20. PubMed ID: 16275594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
    Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).
    Zeigler ZR; Rosenfeld CS; Andrews DF; Nemunaitis J; Raymond JM; Shadduck RK; Kramer RE; Gryn JF; Rintels PB; Besa EC; George JN
    Am J Hematol; 1996 Dec; 53(4):213-20. PubMed ID: 8948657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic microangiopathy following bone marrow transplantation.
    Pettitt AR; Clark RE
    Bone Marrow Transplant; 1994 Oct; 14(4):495-504. PubMed ID: 7858524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes.
    Roy V; Rizvi MA; Vesely SK; George JN
    Bone Marrow Transplant; 2001 Mar; 27(6):641-6. PubMed ID: 11319595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplant-associated thrombotic microangiopathy: a case series.
    Zeigler ZR; Shadduck RK; Nemunaitis J; Andrews DF; Rosenfeld CS
    Bone Marrow Transplant; 1995 Feb; 15(2):247-53. PubMed ID: 7773214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
    Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombotic microangiopathy (TMA) (1). TMA in the target organs of graft-versus-host disease].
    Hirabayashi N
    Rinsho Ketsueki; 2000 Jun; 41(6):491-5. PubMed ID: 10921348
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
    Arranz R; Conde E; Rodriguez-Salvanés F; Pajuelo FJ; Cabrera R; Sanz MA; Petit J; Bueno J; Maldonado J; Odriozola J; Conde JG; Brunet S; Carreras E; Iriondo A; Fernández-Rañada JM; Marín P;
    Bone Marrow Transplant; 2002 Feb; 29(3):205-11. PubMed ID: 11859392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation.
    Srivastava A; Gottlieb D; Bradstock KF
    Bone Marrow Transplant; 1995 Jun; 15(6):863-7. PubMed ID: 7581082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses.
    Milone J; Napal J; Bordone J; Etchegoyen O; Morales V
    Bone Marrow Transplant; 1998 Nov; 22(10):1019-21. PubMed ID: 9849701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.